Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02570139 · ClinicalTrials.gov registry record · NA
Clinical Study to Assess a New Barrier Film's Ability to Provide Skin Protection Against Incontinence & Allow Healing
A NA study, sponsored by Solventum US.
- Terminated
- Registry status
- NA
- Development phase
- 45
- Enrollment target
NCT02570139: Clinical Trial NA study, sponsored by Solventum US.
NCT02570139 is a NA study that was terminated before completion, run by Solventum US. The registered enrollment target is 45 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02570139, a NA study, was terminated before completion, sponsored by Solventum US.
- TERMINATED
- Registry status
- NA
- Development phase
- 45 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety and efficacy of the investigational product (3M™ Cavilon™ Advanced High Endurance Skin Protectant) for the treatment of incontinence associated dermatitis.
Primary Outcome
Primary endpoint was percent decrease in Incontinence Associated Dermatitis (IAD) score from baseline to end of subject's participation. A negative value indicates increased IAD score; a positive value indicates decreased IAD score. IAD scores were calculated for 6 anatomical zones for color, presence of lesions, and skin loss using 3M's Skin Condition Assessment Tool. Skin condition assessed for 1) epidermal loss depth \& area involved; 2) skin color intact skin \& % area if not normal color. I
Interventions
- DEVICE Cavilon Advanced Skin Protectant
- DEVICE ConvaTec Sensi-Care Protective Barrier
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-10 |
| Est. Completion | 2017-06-23 |
| Phase | NA |
Why NCT02570139 stopped before completion
NCT02570139 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 2 interventions - of which Cavilon Advanced Skin Protectant is the first listed.
NCT02570139 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02570139 about?
NCT02570139 is a clinical study titled "Clinical Study to Assess a New Barrier Film's Ability to Provide Skin Protection Against Incontinence & Allow Healing". The purpose of the study is to evaluate the safety and efficacy of the investigational product (3M™ Cavilon™ Advanced High Endurance Skin Protectant) for the treatment of incontinence associated dermatitis.
What is the current status of trial NCT02570139?
This trial is currently terminated. It is a NA study. The enrollment target is 45 participants. The study started on 2015-10. Estimated completion is 2017-06-23.
What interventions are being tested in trial NCT02570139?
The interventions under investigation include: Cavilon Advanced Skin Protectant (DEVICE), ConvaTec Sensi-Care Protective Barrier (DEVICE).
Who is sponsoring clinical trial NCT02570139?
This trial is sponsored by Solventum US, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02570139's enrollment target sits among peer trials
45 1411th of 2000 higher than 578 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia